OTC$ZOMDF
Zomedica Corp · Q3 2025 earnings
Q3 2025 earnings · · Investor relations
Briefing
Zomedica reported Q3 2025, revenue of $8.1M, a net loss of $6.1M.
For Q3 2025, Zomedica reported revenue of $8.1M, a net loss of $6.1M. Management discussed operating trends, liquidity, and priorities as disclosed in the quarterly filing.
- Revenue $8.1M.
- Net loss $6.1M.
- Zomedica updated strategic and capital priorities in the filing.
Headline financials
Revenue & EPS history
Zomedica · Revenue · Quarterly
$8.1M
Forward guidance
The filing discusses Zomedica's outlook, capital deployment, and key risks without relying solely on numeric EPS guidance.
Tailwinds
- Zomedica cited execution on strategic priorities in the filing.
- Balance sheet and liquidity support continued operations.
- Pipeline milestones and partnerships remain key value drivers.
Headwinds
- GAAP profitability remained under pressure in the quarter.
- Macro, competitive, and cost pressures may affect margins.
- Segment mix and one-time items can affect comparability.
- Pre-commercial or early-stage spend continues ahead of sustainable product revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
-1.2%
Avg return
Earnings day
+2.3%
Avg return
5 days after
-1.6%
Avg return
30 days after
27%
9 / 33 earnings
Positive
+41.0%
Q4 2024
Best reaction
-16.9%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -8.2% | -4.0% | -5.1% | |
| Q3 2025 | +1.3% | +26.3% | +50.0% | |
| Q1 2025 | -16.9% | -20.3% | -22.0% | |
| Q4 2024 | +41.0% | +113.9% | +41.7% | |
| Q3 2024 | -1.4% | +14.8% | +3.3% | |
| Q2 2024 | -5.3% | -11.6% | -14.8% | |
| Q1 2024 | -16.8% | -11.0% | -9.1% | |
| Q4 2023 | -4.0% | -4.1% | -2.7% | |
| Q3 2023 | -4.4% | -7.2% | -6.7% | |
| Q2 2023 | -2.3% | -3.9% | -12.2% | |
| Q1 2023 | -8.8% | -8.2% | -10.5% | |
| Q4 2022 | -4.3% | -16.5% | -10.7% | |
| Q3 2022 | -5.3% | -10.0% | -19.6% | |
| Q2 2022 | -10.3% | -28.8% | -38.2% | |
| Q1 2022 | -5.5% | +5.3% | +28.7% | |
| Q4 2021 | +3.1% | -4.7% | -6.4% | |
| Q3 2021 | -2.2% | -6.6% | -30.0% | |
| Q2 2021 | -10.3% | -19.3% | +2.9% | |
| Q1 2021 | -15.3% | -8.2% | +11.4% | |
| Q4 2020 | +11.4% | +9.7% | -8.6% | |
| Q3 2020 | +19.7% | +112.7% | +106.3% | |
| Q2 2020 | -2.8% | -14.1% | -28.8% | |
| Q1 2020 | +14.6% | -1.7% | -12.3% | |
| Q4 2019 | -0.0% | -18.0% | -32.8% | |
| Q3 2019 | -2.4% | +0.6% | +0.6% | |
| Q2 2019 | +0.0% | +0.0% | +68.0% | |
| Q1 2019 | -2.0% | -6.9% | -7.8% | |
| Q4 2018 | +2.0% | +2.0% | -66.6% | |
| Q3 2018 | -7.5% | -8.6% | -15.5% | |
| Q2 2018 | -3.2% | -1.4% | +0.9% | |
| Q1 2018 | +0.0% | — | — | |
| Q4 2017 | +0.7% | — | — | |
| Q3 2017 | +7.0% | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro